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The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis of many transformed but
also of non-transformed cells. In addition, TRAIL receptor activation has been reported to activate non-apoptotic
signaling pathways. Here, we report an increased expression of TRAIL in peripheral blood T cells and monocytes
from patients with atopic dermatitis (AD) compared with control individuals. High TRAIL expression was also
observed in skin-inﬁltrating T cells of AD patients. Topical tacrolimus treatment reduced the total number of T cells
in the skin, but the relative proportion of TRAIL-positive cells within both CD4þ and CD8þ cell populations did not
change. TRAIL was demonstrated to induce the expression of interleukin-1 receptor antagonist (IL-1Ra) in ker-
atinocytes in a caspase-independent manner in vitro. Moreover, increased expression of IL-1Ra was observed in
keratinocytes of AD lesional skin. These data suggest that TRAIL-expressing inﬂammatory skin cells may con-
tribute to the epidermal activation of the IL-1Ra gene in AD.
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Atopic dermatitis (AD) is characterized by chronic or re-
lapsing eczematous lesions with a typical morphology and
distribution, as well as by pruritus (Leung and Bieber, 2003).
In the dermis of AD lesions, there is a marked perivascular T
cell infiltrate (Braathen et al, 1979; Leung et al, 1983), in
which both CD4þ and CD8þ T cells are present (Akdis
et al, 1999). The infiltrating T cells express pro-inflammatory
cytokines, in particular, interleukin (IL)-5 and IL-13 (Hamid
et al, 1994, 1996). In chronic lesions, IFN-g-producing cells
have also been described (Grewe et al, 1994; Trautmann
et al, 2000), despite a reduced capacity of peripheral blood
mononuclear cells (PBMC) to generate this cytokine under
in vitro conditions (Simon et al, 2002, 2003). Because Tcells
are believed to play a pivotal role in the pathogenesis of AD,
they are considered as primary targets of current anti-in-
flammatory treatment strategies in this disease (Tomi and
Luger, 2003; Simon et al, 2004).
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a member of the tumor necrosis factor (TNF) su-
perfamily, and has been implicated in the regulation of var-
ious physiological and pathological immune responses
(Kimberley and Screaton, 2004). This might, at least par-
tially, be because of its wide expression among cells of the
immune system, including activated T cells (Mariani and
Krammer, 1998; Thomas and Hersey, 1998; Kayagaki et al,
1999a; Mirandola et al, 2004), B cells (Mariani and Krammer,
1998; Kemp et al, 2004), monocytes (Griffith et al, 1999;
Halaas et al, 2004; Tecchio et al, 2004), dendritic cells
(Fanger et al, 1999), natural killer cells (Zamai et al, 1998;
Kayagaki et al, 1999b; Mirandola et al, 2004), and ne-
utrophils (Renshaw et al, 2003; Matsuyama et al, 2004;
Tecchio et al, 2004). Most of these studies, however, were
performed in vitro and little is known about TRAIL expres-
sion under in vivo conditions.
TRAIL originally received considerable attention follow-
ing the observation that it selectively induced apoptosis in
cancer but not in normal cells (Ashkenazi et al, 1999;
Walczak et al, 1999). Therefore, TRAIL is considered as a
promising future drug for cancer patients. But recent work
suggests that TRAIL also has several physiological func-
tions that are not limited to the killing of transformed cells.
For instance, TRAIL has been shown to induce apoptosis in
several primary cells, such as hepatocytes (Jo et al, 2000;
Zheng et al, 2004), HIV-activated T cells (Miura et al, 2001),
plasma cells (Ursini-Siegel et al, 2002), immature dendritic
cells (Leverkus et al, 2000), and neutrophils (Renshaw et al,
2003; Matsuyama et al, 2004). Moreover, TRAIL has been
shown to activate a caspase-independent signaling path-
way leading to the activation of nuclear factor-kB (NF-kB)
(Ehrhardt et al, 2003; Leverkus et al, 2003a).
The IL-1 family consists of five members, the pro-in-
flammatory cytokine IL-1 (IL-1a and IL-1b), two IL-1 recep-
tors, and the IL-1 receptor antagonist (IL-1Ra). Whereas IL-
1 exerts a broad spectrum of functional activities, IL-1Ra
fails to activate cells after binding to the IL-1 receptor
(Arend, 2002). The ratio between IL-1 and IL-1Ra seems to
be crucial for the intensity of the inflammatory response in
Abbreviations: AD, atopic dermatitis; IL, interleukin; IL-1Ra, IL-1
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many diseases. To lower this ratio, therapeutic trials with IL-
1Ra have been carried out (Dinarello, 2003).
Here, we report a dramatically increased expression of
TRAIL by several immune cells, in particular, CD4þ and
CD8þ blood and skin T cells, in AD. The increased ex-
pression of TRAIL by immune cells was associated with
increased expression of IL-1Ra by keratinocytes. A poten-
tial link between these two phenomena was shown by the
observation that TRAIL-induced IL-1Ra gene expression in
keratinocytes in vitro. Therefore, T cells may, besides their
pro-inflammatory activities, also exert anti-inflammatory ef-
fects in AD.
Results
Leukocytes of AD patients express increased levels of
TRAIL We examined the surface expression of TRAIL by
flow cytometry using a specific anti-TRAIL monoclonal an-
tibody (mAb). CD4þ and CD8þ T cells as well as CD14þ
monocytes were identified using mAb against the corre-
sponding lineage-associated molecules within PBMC pop-
ulations. Neutrophils and eosinophils were analyzed after
isolation. TRAIL expression in both CD4þ and CD8þ T
cells as well as in monocytes was significantly higher in AD
patients compared with normal controls (Table I), which
usually demonstrated little TRAIL expression (Fig 1). In par-
ticular, CD8þ T cells expressed large amounts of TRAIL in
AD. Interestingly, strong TRAIL expression was also often
Table I. Relative surface expression of TRAIL on blood cells as
assessed by ﬂow cytometry
Cell type Controls AD patients p
Monocytes 1.24  0.09 (9)a 4.59  1.45 (9) 0.0003
CD8þ T cells 1.37  0.23 (5) 10.04  5.27 (5) 0.0079
CD4þ T cells 1.02  0.01 (5) 6.22  1.77 (5) 0.0079
Eosinophils 1.07  0.06 (6) 1.44  0.16 (5) 0.0556
Neutrophils 1.03  0.02 (6) 2.44  0.47 (5) 0.0159
aData represent the mean ratios (  SEM) of mean fluorescence in-
tensities (anti-TRAIL mAb per control mAb) of (n) independent experi-
ments. Representative original data are shown in Fig 1.
TRAIL, the tumor necrosis factor-related apoptosis-inducing ligand;
AD, atopic dermatitis; mAb, monoclonal antibody.
Figure 1
Expression of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in different subsets of blood cells. Cells were isolated
from atopic dermatitis patients and normal donors. Monocytes, CD8þ cells, and CD4þ cells were analyzed within PBMC and identified using anti-
CD14, anti-CD8, and anti-CD4 monoclonal antibody (mAb), respectively. TRAIL expression on neutrophils and eosinophils was analyzed using
purified cell populations. TRAIL expression was measured by flow cytometry using mouse anti-TRAIL mAb (red). Control IgG1 mAb staining is
shown in gray. Three representative and independent experiments for each cell type. Statistical analysis of these experiments is provided in Table I.
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observed in eosinophils and neutrophils from AD patients,
but only exceptionally in control individuals.
Dermal-inﬁltrating T cells express TRAIL in AD To in-
vestigate whether T cells express TRAIL under in vivo con-
ditions, we examined biopsies from lesional skin of AD
patients. As assessed by double immunofluorescence
staining and confocal microscopy, we observed TRAIL ex-
pression in both CD4þ and CD8þ cells. As observed in
blood T cells, the proportion of TRAIL-expressing cells was
higher in CD8þ (mean: 60%) compared with CD4þ (mean:
33%) cells. Therefore, although less CD8þ than CD4þ
cells infiltrated into the skin, the absolute numbers of TRAIL-
expressing cells were approximately the same in both T cell
subgroups (Fig 2). After topical treatment with tacrolimus
0.1% ointment, the numbers of infiltrating T cells signifi-
cantly declined; however, the proportion of TRAIL-express-
ing cells in both CD4þ and CD8þ cells did not change (Fig
2). In contrast, other cytokines such as IL-5 and IL-13 were
reduced as a consequence of this therapy (Simon et al,
2004).
The epidermis of AD lesions exhibits increased IL-1Ra
expression Previously published work suggested that ker-
atinocytes express IL-1Ra (Leverkus et al, 2003a). We com-
pared the expression of IL-1Ra by keratinocytes in skin
biopsies from AD patients and normal controls by immuno-
fluorescence. The expression of IL-1Ra in the epidermis of
AD lesions was much stronger compared with tacrolimus-
treated AD skin and normal skin (Fig 3). The staining was
localized intracellularly. Whereas in lesional skin, positive
cells were distributed throughout the epidermis including
the basal layer, in normal skin the positive cells were sit-
uated above the basal layer.
TRAIL induces IL-1Ra production in keratinocytes in
vitro As TRAIL–TRAIL receptor interactions have recently
been implicated as a negative regulatory mechanism in im-
mune responses (Diehl et al, 2004), we analyzed IL-1Ra
expression in HaCaT keratinocytes following stimulation
with TRAIL. TRAIL-mediated IL-1Ra gene induction was
analyzed by determining mRNA levels at different time
points following TRAIL stimulation using multiprobe rib-
onuclease protection assays. We detected a 2–3-fold in-
duction of IL-1Ra (Fig 4A), whereas the steady-state mRNA
levels of IL-1a, IL-1b, or MCP-1 remained unchanged (data
not shown), confirming our previous findings (Leverkus et al,
2003a). The pan-caspase inhibitor zVAD had no effect in
this system, indicating that TRAIL-mediated transcriptional
activation of IL-1Ra is caspase independent. To determine
whether the expression of IL-1Ra mRNA correlates with
protein expression, we also analyzed IL-1Ra protein ex-
pression in supernatants of HaCaT keratinocytes as well as
primary keratinocytes by using an immunoassay. A 3–10-
fold induction of IL-1Ra protein was found following TRAIL
stimulation of these cells for 24 h (Fig 4B and C). In order to
verify TRAIL-specific induction of IL-1Ra, the same exper-
iments were performed in the presence of 10 mg per mL of
TRAIL-R2-Fc (to block TRAIL) or control IgG as described
(Leverkus et al, 2003a). Preincubation with TRAIL-R2-Fc
fully abrogated TRAIL-induced IL-1Ra induction in both Ha-
CaT and primary keratinocytes. Furthermore, additional
control experiments were performed with TNF-R2-Fc,
which was ineffective in blocking TRAIL-induced IL-1Ra
(data not shown). Taken together, these data suggest that
TRAIL induces IL-1Ra expression in human keratinocytes in
a caspase-independent manner.
Discussion
Because of the crucial role of IL-1Ra in the prevention of
massive tissue damage during inflammatory responses, its
regulation has been investigated by many groups under
both physiological and pathophysiological conditions. IL-
1Ra is found in large amounts in the blood during inflam-
mation and it is primarily generated in the liver (Arend,
2002). Many other cells, however, including monocytes,
macrophages, and neutrophils produce IL-1Ra (Malyak
et al, 1998). Moreover, structural cells such as epithelial
Figure 2
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
expression in atopic dermatitis (AD). (A) Representative double
immunofluorescence stainings of skin biopsy specimens from AD pa-
tients using CD4þ , CD8þ , and TRAIL mAb. White bars, 10 mM. (B)
Bars indicate mean numbers of total and TRAIL-positive CD4þ and
CD8þ cells of 10 patients in the dermal infiltrate of lesional skin before
and after treatment with topical tacrolimus.
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cells, fibroblasts, and endothelial cells are also IL-1Ra pro-
ducers (Haskill et al, 1991; Corradi et al, 1995).
In this study, we obtained evidence that keratinocytes
express IL-1Ra under physiological conditions. This con-
firms previous work, suggesting IL-1 and IL-1Ra expression
by keratinocytes (Leverkus et al, 2003a). In psoriasis, IL-1Ra
expression by keratinocytes was elevated, resulting in an
increased IL-Ra/IL-1 ratio (Hammerberg et al, 1992; Kris-
tensen et al, 1992; Debets et al, 1997). Here we report an
increased expression of IL-1Ra in the epidermis of AD pa-
tients, suggesting that the transcriptional activation of this
anti-inflammatory gene is a general phenomenon in in-
flamed skin independent of the underlying pathomecha-
nism. IL-1Ra may limit the inflammatory response in the skin
and thereby skin damage.
The regulation of IL-1Ra gene expression in keratin-
ocytes is unclear. It is possible that IL-1 induces IL-1Ra
Figure 3
Representative immunofluorescence
stainings of interleukin-1 receptor an-
tagonist (IL-1Ra) in the skin. Staining
with an anti-IL-1RA Ab reveals strong
positive cells throughout the epidermis
of lesional AD skin. Nuclei were counter-
stained with propidium iodide. After treat-
ment, few keratinocytes in the suprabasal
layers stained weakly positive. Weak
staining was also observed in normal
skin. The white dashed line indicates the
border between the epidermis and the
dermis. The original magnification is indi-
cated in each panel.
Figure4
Interleukin-1 receptor antagonist (IL-1Ra) expression following
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
stimulation of keratinocytes. (A) Following preincubation with either
diluent alone or 40 mM zVAD-fmk for 1 h, HaCaTcells were treated with
recombinant TRAIL (500 ng per mL) for the indicated times. Multiprobe
RPA (RiboQuant) were performed using 5 mg of total RNA. Steady-state
levels for IL-1Ra were determined by normalizing against the expres-
sion of the L32 housekeeping gene. (B) TRAIL-induced IL-1Ra secre-
tion in HaCaT cells. Cells were preincubated with either diluent alone
(control) in the presence or absence of 10 mg per mL of TRAIL-R2-Fc or
control IgG for 1 h, and subsequently treated with 500 ng per mL
recombinant TRAIL for 24 h. Cell-free supernatants were collected and
assayed for IL-1Ra by ELISA. (C) TRAIL-induced IL-1Ra secretion in
primary keratinocytes. Cells were preincubated with either diluent alone
(control) in the presence or absence of 10 mg per mL of TRAIL-R2-Fc or
control IgG for 1 h, and subsequently treated with the indicated con-
centrations of recombinant TRAIL for 24 h. Cell-free supernatants were
collected and assayed for IL-1Ra by ELISA. Two independent exper-
iments are shown.
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expression in these cells as it does in other cell types (La
and Fischer, 2001). To increase the IL-1Ra/IL-1 ratio, how-
ever, additional factors are probably involved. One such
factor could be TRAIL, which, as demonstrated in this study,
transcriptionally activated the IL-1Ra but not the IL-1 gene.
It is possible that IL-1Ra gene induction involves the acti-
vation of NF-kB (Leverkus et al, 2003a).
TRAIL has been shown to be critical in the regulation of
the immune response as it induced apoptosis in dendritic
cells, regulating adaptive immune response (Fanger et al,
1999). The fact that TRAIL mediates apoptosis in ne-
utrophils (Renshaw et al, 2003; Matsuyama et al, 2004;
Tecchio et al, 2004) suggests that it also controls innate
immune responses. Moreover, TRAIL-deficient mice
showed increased susceptibility to experimentally induced
autoimmune arthritis (Lamhamedi-Cherradi et al, 2003b)
and diabetes (Lamhamedi-Cherradi et al, 2003a). On the
other hand, TRAIL application improved clinical signs of
experimental arthritis (Liu et al, 2003) and autoimmune en-
cephalitis (Hilliard et al, 2001). Furthermore, in vitro activat-
ed PBMC from AD patients with poor responses to
corticosteroids demonstrated low TRAIL levels compared
with AD patients with good clinical efficacy (Heishi et al,
2002). Altogether, these data point to the possibility that
TRAIL exerts anti-inflammatory activities, which may in-
clude the induction of apoptosis in inflammatory cells (Jo
et al, 2000; Leverkus et al, 2000; Miura et al, 2001; Ursini-
Siegel et al, 2002; Renshaw et al, 2003; Matsuyama et al,
2004; Zheng et al, 2004), blocking of the cell cycle (Song
et al, 2000), activation of inhibitory phosphatases (Daigle
et al, 2002), and, perhaps, as this report suggests, the in-
ducible expression of IL-1Ra.
In spite of the recent progress in the field, the physio-
logical role of TRAIL remains to be determined. In this study,
we demonstrate increased TRAIL expression by several in-
flammatory cells under ex vivo and in vivo conditions in AD.
To our knowledge, there are no previous reports on the ex-
pression of TRAIL under inflammatory conditions. In addi-
tion, we observed that anti-inflammatory therapy with
tacrolimus did not decrease the relative proportion of
TRAIL-expressing skin-infiltrating T cells in AD. To better
understand TRAIL functions, expression studies in other
diseases should be performed and controlled following
pharmacological treatment. Further experimentation is re-
quired to determine more precisely the role of TRAIL in the
regulation of the IL-1Ra/IL-1 system.
Materials and Methods
Subjects Ten patients (18–58 y) with moderate-to-severe AD ful-
filling the diagnostic criteria (Hanifin and Rajka, 1980) were includ-
ed. Skin biopsies were taken from acute lesions before therapy and
1–3 wk after starting therapy with tacrolimus 0.1% ointment twice
daily. At the same time points, 20 mL heparin-anticoagulated blood
samples were obtained. Nine healthy individuals served as con-
trols. All patients signed a written informed consent. The study was
approved by the medical ethical committee of the canton Bern. It
was conducted according to the Declaration of Helsinki Principles.
Cells PBMC and neutrophils were purified by Ficoll–Hypaque
centrifugation (Simon et al, 2002; Baumann et al, 2003; Altznauer
et al, 2004). Eosinophils were isolated by immunomagnetic selec-
tion with anti-CD16 mAb-conjugated beads as described previ-
ously (Dibbert et al, 1998; Simon et al, 2003). The resulting cell
populations contained more than 98% eosinophils and neutrophils,
respectively. HaCaT cells (a kind gift from Dr N. Fusenig, Heidelb-
erg, Germany) were maintained in DMEM (Invitrogen, Basel, Swit-
zerland) containing 10% fetal calf serum.
Flow cytometry Purified PBMC, neutrophils, and eosinophils
were stained with mouse anti-TRAIL mAb (clone 2E5, Alexis Cor-
poration, Basel, Switzerland). Briefly, 1  105 cells were incubated
with 10 mg per mL of anti-TRAIL mAb and IgG1 control mAb (Alexis
Corporation), respectively, on ice for 45 min. After three washings
with staining buffer (PBS, 0.4% of BSA), cells were incubated with
anti-mouse PE-conjugated Ab for 30 min, washed, and analyzed
by a standard flow cytometric technique using FACS Calibur (Bec-
ton Dickinson, Heidelberg, Germany). To determine lymphocyte
and monocyte subsets, PBMC were additionally stained with FITC-
conjugated anti-CD8 and anti-CD14 mAb, respectively, or with
APC-conjugated anti-CD4 mAb. Collected data were analyzed by
FlowJo software (Tree Star, Ashland, Oregon). Except anti-TRAIL
and control IgG1 mAb, all Abs were obtained from Becton Dickin-
son Biosciences (Basel, Switzerland).
Confocal microscopy Immunofluorescence staining was per-
formed on 4 mm sections of paraformaldehyde-fixed and paraf-
fin-embedded skin biopsies as described previously (Simon et al,
2004). To identify TRAIL-expressing T cells in the dermal infiltrate,
sections were treated with mAb against CD4 and CD8 (Serotec,
Oxford, UK) at 41C overnight. TRAIL expression was analyzed by
using a polyclonal Ab against human TRAIL (Alexis Corporation). To
identify IL-1Ra in the epidermis, a polyclonal Ab against IL-1Ra
(Santa Cruz Biotechnology, Santa Cruz, California) was used. Ab
binding was detected with appropriate tetramethyl rhodamine is-
othiocyanate-conjugated and fluorescein isothiocyanate-conjugat-
ed secondary Abs (Milan Analytica AG, distributed by La Roche,
Basel, Switzerland). Nuclei were counterstained with propidium
iodide (Sigma, Buchs, Switzerland). The immunofluorescent staining
was viewed by two independent investigators using a confocal laser
scanning microscope (LSM 510, Carl Zeiss, Heidelberg, Germany).
RNase protection assay (RPA) Total RNA was extracted using
the Qiagen RNEasy Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s recommendation. Five micrograms of total RNA
was processed according to PharMingen’s RiboQuant protocol for
mRNA expression of IL-1Ra (San Diego, California). L32 mRNA
was used as a loading control.
ELISA IL-1Ra secretion from keratinocyte cultures was analyzed
by ELISA (R&D Systems, Wiesbaden, Germany) as described pre-
viously (Leverkus et al, 2003b). Briefly, HaCaT cells (in DMEM) as
well as primary keratinocytes (in keratinocyte growth medium 2;
PromoCell, BioConcept, Allschwil, Switzerland) from two inde-
pendent donors (Euroderm GmbH, Leipzig, Germany) were seeded
in 48-well plates at a density of 3  104 and maintained at 371C for
24 h. Plates were washed, and stimulation with recombinant LZ-
TRAIL (a kind gift from Dr H. Walczak, Heidelberg, Germany) was
performed under serum-free conditions for an additional 24 h. Cell-
free supernatants were analyzed by ELISA according to the rec-
ommendations of the manufacturer normalized to protein secretion
present in control cultures.
Statistical analysis All statistical analyses were performed with
Graph Pad Prizm (GraphPad Software, San Diego, California).
Data are presented as means  SEM. To compare groups as well
as results before and after therapy, unpaired and paired t tests
were applied. A probability (p) value below 0.05 was considered
significant.
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